A 72-Year-Old Man With Heavily Pretreated, Relapsed/Refractory Multiple Myeloma
Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.
A 72-Year-Old Man with Heavily Pretreated, R/R Multiple Myeloma
Initial Presentation
- A 72-year-old man diagnosed with multiple myeloma 4.5 years ago returns for routine follow up
- Treatment history:
- Initially treated with VRd for 12 months, followed by lenalidomide maintenance 15 mg daily; stable disease lasting 36 months
- Rechallenged with VRd, stable disease lasting 20 months
- Subsequently switched to KPd, achieved a partial response lasting 15 months
- Started DVd; follow up at 12 months showed M protein increase by 0.5 g/dl; patient continues to feel well
- Currently, 3 months after his last visit, he returns to the clinic complaining of increased muscle weakness, fatigue and bone pain
- PE: new bony tenderness appreciated on ribs, bruising, mild bleeding of the gums
Clinical Workup
- Labs: Hb 8.8 g/dL, calcium 10.2 mg/dL, LDH 160 U/L, creatinine 2.1 mg/dL, albumin 3.0 g/dL, b2 microgloblulin 4.9 mcg/mL, serum M-protein 4.2 g/dL, lambda free light chains 4.1 mg/dL
- HBV negative
- Skeletal survey and MRI revealed stable lytic bone lesions in the left hip, pelvis and L2 vertebrae and new lytic lesions on the ribs 4 and 10 on the left side
- Bone marrow shows 70% plasma cells IgG k
- FISH: t(6;14) (p21;q32) at diagnosis; new del(17p)
- Diagnosis: R-ISS stage II MM
- ECOG 1
Treatment
- Initiated treatment with belantamab mafodotin
Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma
December 17th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Read More
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
